MyFinsight
Home
Blog
About
Acquired ipr&d related to
emalex biosciences,...
$724M
Depreciation and
amortization
$241M
(-3.60%↓ Y/Y)
Impairment of long-lived
assets and assets held...
$112M
(12.00%↑ Y/Y)
Stock-based compensation
$40M
(5.26%↑ Y/Y)
Deferred income taxes net
and uncertain tax...
$25M
(111.85%↑ Y/Y)
Other items
$18M
(-82.35%↓ Y/Y)
Net cash provided by
(used in) operating...
$411M
(81.06%↑ Y/Y)
Canceled cashflow
$750M
Net change in cash
and cash...
-$86M
(-118.53%↓ Y/Y)
Canceled cashflow
$411M
Beneficial interest
collected in exchange for...
$311M
(-7.44%↓ Y/Y)
Proceeds from sale of
business and long-lived...
$4M
(-55.56%↓ Y/Y)
Net income (loss)
-$575M
(-303.18%↓ Y/Y)
Net change in
operating assets and...
$163M
(-51.34%↓ Y/Y)
Net loss (gain) from
sale of business and...
$12M
Net cash provided by
(used in) investing...
-$492M
(-308.47%↓ Y/Y)
Canceled cashflow
$315M
Effect of exchange rate
changes on cash and cash...
-$5M
(0.00%↑ Y/Y)
Purchase of emalex
biosciences outstanding...
$696M
Purchases of property,
plant and equipment...
$105M
(9.38%↑ Y/Y)
Other investing
activities
$4M
(233.33%↑ Y/Y)
Purchases of investments
and other assets
$1M
(-93.75%↓ Y/Y)
Back
Back
Cash Flow
logo_teva-svg
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
logo_teva-svg
source: myfinsight.com
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)